Compare Gilead Sciences, Inc. (GILD) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Modine Manufacturing Company — how do they compare? Gilead Sciences, Inc. trades at $135.86 (market cap $163.51B), while Modine Manufacturing Company trades at $224.68 (market cap $12.32B). The key difference: Gilead Sciences, Inc. is far larger — about 13.3× Modine Manufacturing Company's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| GILD | MOD | |
|---|---|---|
Market Cap | $163.51B | $12.32B |
Sector | Health | Technology |
52-Week High | $155.80 | $306.89 |
52-Week Low | $108.22 | $91.30 |
Enterprise Value | $178.05B | $12.68B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Modine (MOD) trades at $222.31, down 3.16% with bearish technical signals, though it has beaten earnings estimates for three consecutive quarters. The company reported 2025 revenue of $2.58B with a net income margin of 3.82%, but faces a high P/E ratio of 102.64. Recent news includes the appointment of a new Commercial HVAC president and an upcoming Q1 2027 earnings call on July 30, 2026.
Analyst consensus is strongly bullish with a $328.80 price target, but high valuation and projected margin compression in 2026 present risks. The stock's near-term direction may hinge on Q2 2026 earnings versus the $1.38 estimate and execution in the data center and HVAC segments amid supply chain challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
